Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Colorcon
McKinsey
Dow

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR RIOCIGUAT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Riociguat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00855660 ↗ Effect of Riociguat on Bone Metabolism Completed Bayer Phase 1 2009-03-01 Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism.
NCT01014247 ↗ Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation Completed Bayer Phase 1 2009-11-01 The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).
NCT01065051 ↗ Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics Terminated Bayer Phase 2 2010-11-01 The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
NCT01065454 ↗ A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction Active, not recruiting Bayer Phase 2 2010-04-14 The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
NCT01165931 ↗ Coronary Vasomotor Response After Riociguat Exposure Withdrawn Bayer Phase 2 2012-05-01 The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.
NCT01172756 ↗ A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction Terminated Bayer Phase 2 2010-07-01 The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
NCT01179334 ↗ Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. Completed Bayer Phase 2 2010-08-01 Pulmonary Arterial Hypertension (PAH) is a severe progressive disease with a high mortality. Although several drugs are available for the treatment of PAH none offer a cure, therefore there is still a high medical need for new treatments. Soluble guanylate cyclase (sGC) is one of the chemicals involved in the pathways controlling vascular tone, which is impaired in patients with PAH. This causes constriction and thickening of the blood vessels wall in the lungs and increase of blood pressure in the lungs. This can lead to the very debilitating symptoms of PAH such as tiredness, shortness of breath on exertion, collapse and often the inability of the patient to perform their daily life activities. Inhalation of Nitric Oxide, which activates sGC is used to treat PAH, but its effect wears off as soon as inhalation stops. Direct stimulation of sGC using this new compound Riociguat may be a new approach for the treatment of PAH. The phosphodiesterase 5 (PDE5)-inhibitor Sildenafil is one of licensed treatments for PAH. The Patent Plus is a double-blind, placebo-controlled safety study, designed to investigate the effect of Riociguat on blood pressure in patients with PAH when given in combination with Sildenafil.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Riociguat

Condition Name

Condition Name for Riociguat
Intervention Trials
Hypertension, Pulmonary 13
Chronic Thromboembolic Pulmonary Hypertension 5
Ventricular Dysfunction, Left 3
Pharmacology, Clinical 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Riociguat
Intervention Trials
Hypertension, Pulmonary 24
Hypertension 24
Pulmonary Arterial Hypertension 8
Familial Primary Pulmonary Hypertension 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Riociguat

Trials by Country

Trials by Country for Riociguat
Location Trials
United States 143
Germany 70
Japan 39
Italy 28
United Kingdom 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Riociguat
Location Trials
Massachusetts 10
California 9
Pennsylvania 9
New York 9
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Riociguat

Clinical Trial Phase

Clinical Trial Phase for Riociguat
Clinical Trial Phase Trials
Phase 4 6
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Riociguat
Clinical Trial Phase Trials
Completed 18
Recruiting 13
Terminated 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Riociguat

Sponsor Name

Sponsor Name for Riociguat
Sponsor Trials
Bayer 27
Merck Sharp & Dohme Corp. 4
Actelion 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Riociguat
Sponsor Trials
Industry 37
Other 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Merck
McKinsey
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.